Anti-Fibrinolytic Drugs - Latvia

Latvia

The Anti-Fibrinolytic Drugs market in Latvia is projected to reach a revenue of US$4.76m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 5.33%, resulting in a market volume of US$6.17m by 2029.
In global comparison, United States is anticipated to generate the highest revenue, with US$9,858.00m in 2024.
In Latvia, there is a growing demand for anti-fibrinolytic drugs due to an increase in surgical procedures and a rising prevalence of bleeding disorders.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Fibrinolytic Drugs market in Latvia is showing promising growth in recent years.

Customer preferences: The demand for Anti-Fibrinolytic Drugs is increasing in Latvia due to the rise in the number of patients suffering from bleeding disorders. Additionally, the growing awareness among people about the benefits of Anti-Fibrinolytic Drugs is also contributing to the market growth.

Trends in the market: One of the major trends in the Anti-Fibrinolytic Drugs market in Latvia is the increasing adoption of generic drugs. The availability of cost-effective generic drugs is attracting a large number of patients towards them. Moreover, the growing trend of online pharmacies is also contributing to the market growth in Latvia.Local Special circumstances: Latvia has a well-developed healthcare system that provides universal access to healthcare services to its citizens. The government of Latvia is taking various initiatives to improve the healthcare system in the country. For instance, in 2020, the government announced a new healthcare reform plan that aims to improve the quality of healthcare services and make them more accessible to all citizens.

Underlying macroeconomic factors: The growing population and the increasing prevalence of bleeding disorders in Latvia are the major macroeconomic factors driving the growth of the Anti-Fibrinolytic Drugs market in the country. Additionally, the favorable government policies and the increasing investments in the healthcare sector are also contributing to the market growth.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.